Microwave-accelerated synthesis of p1′-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold

被引：41

作者：

Ekegren, JK

Ginman, N

Johansson, Å

Wallberg, H

Larhed, M

Samuelsson, B

Unge, T

Hallberg, A

机构：

[1] Uppsala Univ, Dept Med Chem, BMC, SE-75123 Uppsala, Sweden

[2] Uppsala Univ, Dept Cell & Mol Biol, BMC, SE-75124 Uppsala, Sweden

[3] Medivir AB, SE-14144 Huddinge, Sweden

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 05期

关键词：

D O I：

10.1021/jm051239z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Two series of P1'-extended HIV-1 protease inhibitors comprising a tertiary alcohol in the transition-state mimic exhibiting K-i values ranging from 2.1 to 93 nM have been synthesized. Microwave-accelerated palladium-catalyzed cross-couplings were utilized to rapidly optimize the P1' side chain. High cellular antiviral potencies were encountered when the P1' benzyl group was elongated with a 3- or 4-pyridyl substituent (EC50 = 0.18-0.22 mu M). X-ray crystallographic data were obtained for three inhibitors cocrystallized with the enzyme.

引用

页码：1828 / 1832

页数：5

共 39 条

[1] HIV protease inhibitors: Peptidomimetic drugs and future perspectives
Abdel-Rahman, HM
Al-karamany, GS
El-Koussi, NA
Youssef, AF
Kiso, Y
[J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (21) : 1905 - 1922
[2] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
Acosta, EP
Kakuda, TN
Brundage, RC
Anderson, PL
Fletcher, CV
[J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 : S151 - S159
[3] Design and fast synthesis of C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1 protease inhibitors
Alterman, M
Andersson, HO
Garg, N
Ahlsén, G
Lövgren, S
Classon, B
Danielson, UH
Kvarnström, I
Vrang, L
Unge, T
Samuelsson, B
Hallberg, A
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) : 3835 - 3844
[4] BALANI SK, 1995, DRUG METAB DISPOS, V23, P266
[5] New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors:: Candidates for clinical development
Bold, G
Fässler, A
Capraro, HG
Cozens, R
Klimkait, T
Lazdins, J
Mestan, J
Poncioni, B
Rösel, J
Stover, D
Tintelnot-Blomley, M
Acemoglu, F
Beck, W
Boss, E
Eschbach, M
Hürlimann, T
Masso, E
Roussel, S
Ucci-Stoll, K
Wyss, D
Lang, R
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3387 - 3401
[6] HIV-1 protease: mechanism and drug discovery
Brik, A
Wong, CH
[J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2003, 1 (01) : 5 - 14
[7] EPITHELIAL-CELL PERMEABILITY OF A SERIES OF PEPTIDIC HIV PROTEASE INHIBITORS - AMINOTERMINAL SUBSTITUENT EFFECTS
CONRADI, RA
HILGERS, AR
BURTON, PS
HESTER, JB
[J]. JOURNAL OF DRUG TARGETING, 1994, 2 (02) : 167 - 171
[8] New approaches toward anti-HIV chemotherapy
De Clercq, E
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) : 1297 - 1313
[9] L-735,524 - THE DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR
DORSEY, BD
LEVIN, RB
MCDANIEL, SL
VACCA, JP
GUARE, JP
DARKE, PL
ZUGAY, JA
EMINI, EA
SCHLEIF, WA
QUINTERO, JC
LIN, JH
CHEN, IW
HOLLOWAY, MK
FITZGERALD, PMD
AXEL, MG
OSTOVIC, D
ANDERSON, PS
HUFF, JR
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) : 3443 - 3451
[10] A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold
Ekegren, JK
Unge, T
Safa, MZ
Wallberg, H
Samuelsson, B
Hallberg, A
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (25) : 8098 - 8102

← 1 2 3 4 →